Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing FLT3 inhibitor and chemotherapeutic agent for treating acute myelogenous leukemia

An acute myeloid system and composition technology, applied in the direction of drug combinations, medical preparations containing active ingredients, pharmaceutical formulas, etc., can solve problems such as poor prognosis and limited long-term curative effect

Pending Publication Date: 2022-06-21
HANMI PHARMA
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, with conventional acute myeloid leukemia (AML) standard chemotherapy, targeting AML stem / progenitor cells is impossible, so the disease often recurs in patients, and thus there is a problem of limited long-term efficacy (Non-Patent Document 2)
Treatment of FLT3- AML patients with ITD mutations also exhibit poorer prognosis (Non-Patent Document 4)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing FLT3 inhibitor and chemotherapeutic agent for treating acute myelogenous leukemia
  • Pharmaceutical composition containing FLT3 inhibitor and chemotherapeutic agent for treating acute myelogenous leukemia
  • Pharmaceutical composition containing FLT3 inhibitor and chemotherapeutic agent for treating acute myelogenous leukemia

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0151] MV-4-11 cell line xenograft mouse model

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided are pharmaceutical compositions for the treatment of acute myelogenous leukemia (AML); and a method for treating acute myelogenous leukemia by using the pharmaceutical composition. The pharmaceutical composition comprises a therapeutically effective combination of: an Fms-like tyrosine kinase-3 (FLT3) inhibitor, or a pharmaceutically acceptable salt or solvate thereof; and a chemotherapeutic agent or a pharmaceutically acceptable salt or solvate thereof.

Description

technical field [0001] The present invention relates to pharmaceutical compositions for the treatment of acute myeloid leukemia comprising effective therapeutic compositions of Fms-like tyrosine kinase-3 (FLT3) inhibitors and chemotherapeutic agents; and methods of treatment using such compositions. Background technique [0002] Fms-like tyrosine kinase-3 (FLT3) is one of the most commonly mutated genes in acute myeloid leukemia (AML). Mutant FLT3 (mutant FLT3) refers to a mutation expressed in leukemia cells present in a subset of acute myeloid leukemia (AML) patients. Activating mutations in FLT3, such as intragenic tandem duplication (ITD) in the proximal domain, appear in about 25-30% of newly diagnosed AML cases (Patent Document 1). FLT3 mutation is known to occur in about one-third of acute myeloid leukemia (AML) patients (Non-Patent Document 1). [0003] Although several FLT3 inhibitors are clinically available, drug-resistant leukocytes have been observed in AML pa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/506A61K31/496A61K45/06A61P35/02
CPCA61K31/506A61P35/02A61K45/06A61K31/00A61K31/496A61K2300/00
Inventor 裵仁焕宋芝英崔载律安永吉
Owner HANMI PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com